• Side Effects of Zanubrutinib

  Zanubrutinib is a targeted therapeutic agent (a Bruton’s tyrosine kinase [BTK] inhibitor) primarily indicated for the treatment of certain B-cell lymp···【Read More】

  Update: 2026-02-04Source: Haiou HealthViews: 90

• How Many Capsules of Zanubrutinib Should I Take Daily?

  The standard dosage of zanubrutinib is oral administration twice daily, 160 mg per dose (equivalent to 2 capsules of 80 mg strength), once in the morn···【Read More】

  Update: 2026-02-04Source: Haiou HealthViews: 78

• Zanubrutinib Medication Information

  Zanubrutinib is currently available as oral capsules and is a precision therapeutic agent. Its core mechanism is to target Bruton's tyrosine kinas···【Read More】

  Update: 2026-02-04Source: Haiou HealthViews: 83

• Four Groups of People Who Should Not Take vebreltinib

  The contraindicated populations for vebreltinib a targeted therapy drug, mainly include those allergic to the drug components, patients with severe he···【Read More】

  Update: 2026-02-03Source: Haiou HealthViews: 74

• Why vebreltinib Should Not Be Taken Casually

  vebreltinib is a targeted therapy agent for specific gene mutations (e.g., MET exon 14 skipping mutation), primarily indicated for non-small cell lung···【Read More】

  Update: 2026-02-03Source: Haiou HealthViews: 86

• How Many Capsules of vebreltinib Should Be Taken at a Time?

  The recommended usual dose of vebreltinib is 2 capsules (50 mg per capsule) taken orally once daily, and the specific dosage must be adjusted strictly···【Read More】

  Update: 2026-02-03Source: Haiou HealthViews: 74

• Adverse Reactions of Vebreltinib Enteric-coated Capsules

  Vebreltinib Enteric-coated Capsules is a targeted therapy agent primarily indicated for the treatment of malignant tumors such as non-small cell lung ···【Read More】

  Update: 2026-02-03Source: Haiou HealthViews: 74

• Package Insert for Vebreltinib

  Vebreltinib is an oral small-molecule MET inhibitor, primarily indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC···【Read More】

  Update: 2026-02-03Source: Haiou HealthViews: 74

• Chidamide Tablets: Indicated Populations

  Chidamide Tablets are a prescription anti-tumor medication primarily indicated for adult patients with specific types of lymphoma and must be used und···【Read More】

  Update: 2026-02-02Source: Haiou HealthViews: 76

• with breast cancer. Precautions for Chidamide Tablets

  Chidamide Tablets is an antineoplastic agent indicated for patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) who have received at···【Read More】

  Update: 2026-02-02Source: Haiou HealthViews: 76

• Adverse Reactions of Chidamide

  Chidamide is a targeted drug indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Its common adverse reactions mai···【Read More】

  Update: 2026-02-02Source: Haiou HealthViews: 79

• Dosage and Administration of Chidamide

  The usual dosage of chidamide is one capsule (5mg) once daily, yet the specific medication must strictly follow the doctor's advice, and the dosag···【Read More】

  Update: 2026-02-02Source: Haiou HealthViews: 74

• Chidamide Package Insert

  Chidamide is a histone deacetylase (HDAC) inhibitor, primarily indicated for the treatment of refractory or relapsed peripheral T-cell lymphoma (PTCL)···【Read More】

  Update: 2026-02-02Source: Haiou HealthViews: 72

• Drug Interactions of Furmonertinib: Contraindicated and Coadministered Medications

  Furmonertinib (a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI targeted therapy drug) has clinically significa···【Read More】

  Update: 2026-01-30Source: Haiou HealthViews: 85

• Precautions for Taking Furmonertinib

  Furmonertinib, a third-generation EGFR-TKI targeted therapeutic agent, should be administered strictly under medical supervision. Particular attention···【Read More】

  Update: 2026-01-30Source: Haiou HealthViews: 80